Chongqing Lummy Pharmaceutical (SHE:300006) — Market Cap & Net Worth
Market Cap & Net Worth: Chongqing Lummy Pharmaceutical (300006)
Chongqing Lummy Pharmaceutical (SHE:300006) has a market capitalization of $987.34 Million (CN¥6.75 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #9171 globally and #2465 in its home market, demonstrating a -0.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chongqing Lummy Pharmaceutical's stock price CN¥6.39 by its total outstanding shares 1055911205 (1.06 Billion). Analyse how efficiently does Chongqing Lummy Pharmaceutical generate cash to see how efficiently the company converts income to cash.
Chongqing Lummy Pharmaceutical Market Cap History: 2015 to 2026
Chongqing Lummy Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $1.65 Billion to $987.34 Million (-2.09% CAGR).
Chongqing Lummy Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chongqing Lummy Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.71x
Chongqing Lummy Pharmaceutical's market cap is 0.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.65 Billion | $963.98 Million | $20.61 Million | 1.71x | 79.89x |
| 2016 | $1.26 Billion | $990.22 Million | $6.98 Million | 1.27x | 179.88x |
| 2017 | $952.53 Million | $1.28 Billion | $55.56 Million | 0.74x | 17.14x |
| 2018 | $545.69 Million | $1.56 Billion | $98.00 Million | 0.35x | 5.57x |
| 2019 | $864.73 Million | $1.86 Billion | -$155.20 Million | 0.47x | N/A |
| 2020 | $1.15 Billion | $1.58 Billion | -$326.76 Million | 0.72x | N/A |
| 2021 | $1.05 Billion | $1.23 Billion | -$100.53 Million | 0.86x | N/A |
| 2022 | $588.69 Million | $884.59 Million | -$68.71 Million | 0.67x | N/A |
| 2023 | $574.79 Million | $895.59 Million | -$8.93 Million | 0.64x | N/A |
| 2024 | $565.52 Million | $795.60 Million | -$87.80 Million | 0.71x | N/A |
Competitor Companies of 300006 by Market Capitalization
Companies near Chongqing Lummy Pharmaceutical in the global market cap rankings as of May 4, 2026.
Key companies related to Chongqing Lummy Pharmaceutical by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
Chongqing Lummy Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Chongqing Lummy Pharmaceutical's market cap moved from $1.65 Billion to $ 987.34 Million, with a yearly change of -2.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥987.34 Million | +24.32% |
| 2025 | CN¥794.20 Million | +40.44% |
| 2024 | CN¥565.52 Million | -1.61% |
| 2023 | CN¥574.79 Million | -2.36% |
| 2022 | CN¥588.69 Million | -44.13% |
| 2021 | CN¥1.05 Billion | -8.21% |
| 2020 | CN¥1.15 Billion | +32.76% |
| 2019 | CN¥864.73 Million | +58.46% |
| 2018 | CN¥545.69 Million | -42.71% |
| 2017 | CN¥952.53 Million | -24.15% |
| 2016 | CN¥1.26 Billion | -23.74% |
| 2015 | CN¥1.65 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Chongqing Lummy Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $987.34 Million USD |
| MoneyControl | $987.34 Million USD |
| MarketWatch | $987.34 Million USD |
| marketcap.company | $987.34 Million USD |
| Reuters | $987.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more